Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1061124.RAKhyyMuijabGscmS50RCRhs265jXbdLypVQvY55u9g8o130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1061124.RAKhyyMuijabGscmS50RCRhs265jXbdLypVQvY55u9g8o130_assertion type Assertion NP1061124.RAKhyyMuijabGscmS50RCRhs265jXbdLypVQvY55u9g8o130_head.
- NP1061124.RAKhyyMuijabGscmS50RCRhs265jXbdLypVQvY55u9g8o130_assertion wasGeneratedBy ECO_0000203 NP1061124.RAKhyyMuijabGscmS50RCRhs265jXbdLypVQvY55u9g8o130_provenance.
- NP1061124.RAKhyyMuijabGscmS50RCRhs265jXbdLypVQvY55u9g8o130_assertion wasDerivedFrom befree-2016 NP1061124.RAKhyyMuijabGscmS50RCRhs265jXbdLypVQvY55u9g8o130_provenance.
- NP1061124.RAKhyyMuijabGscmS50RCRhs265jXbdLypVQvY55u9g8o130_assertion SIO_000772 23502220 NP1061124.RAKhyyMuijabGscmS50RCRhs265jXbdLypVQvY55u9g8o130_provenance.
- NP1061124.RAKhyyMuijabGscmS50RCRhs265jXbdLypVQvY55u9g8o130_assertion evidence source_evidence_literature NP1061124.RAKhyyMuijabGscmS50RCRhs265jXbdLypVQvY55u9g8o130_provenance.
- NP1061124.RAKhyyMuijabGscmS50RCRhs265jXbdLypVQvY55u9g8o130_assertion description "[Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1061124.RAKhyyMuijabGscmS50RCRhs265jXbdLypVQvY55u9g8o130_provenance.